Fakultäten » Vetsuisse-Fakultät » Labortierkunde, Institut für » Prof. Dr. Matthias Barton » Barton

Current research project

Title / Titel Endothelin receptor antagonists as novel therapeutics for chronic kidney disease
PDF Abstract (PDF, 14 KB)
Original title / Originaltitel Endothelin-Rezeptorblockade zur Behandlung chronischer Nierenerkrankungen
Summary / Zusammenfassung Endothelin is involved in the pathogenesis of glomerulosclerosis and proteinuria in experimental animals and humans. Proteinuric renal disease is particularly common among diabetics and hypertensives, but its prevalence is also increase in obesity and aging. Endothelin receptor antagonists (ERAs) have been recently shown to interfere with the disease process, to reverse proteinuria, and even to regress pre-existing glomerulosclerosis. This project studies the molecular mechanisms underlying the anti-proteinuric and nephroprotective effects of ERAs in chronic renal disease.

Supported by SNSF grants Nr. 58 421, Nr. 58 426, Nr. 108 258 and Nr. 122 504
Publications / Publikationen GPER is required for the age-dependent upregulation of the myocardial endothelin system
M.R. Meyer, N.C. Fredette, G. Sharma, M. Barton, E.R. Prossnitz
Life Sci 159, 61-65, 2016

Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy
M. Barton, M. Husmann, M.R. Meyer
Can J Cardiol 32, 680-686, 2016

Endothelin and the glomerulus in chronic kidney disease

M. Barton, A. Sorokin

Semin Nephrol 35, 156-167, 2015

Aging and endothelin: determinants of disease
M. Barton
Life Sci 118, 97-109, 2014

In Memoriam: Wolfgang Kiowski, M.D. (1949-2012) - Pioneer in clinical endothelin research
M. Barton, E.L. Schiffrin
Life Sci 118, 91-96, 2014

25 Years of endothelin research: the next generation
N. Emoto, N. Vignon-Zellweger, R.A. Lopes, J. Cacioppo, L. Debiens, D. Kamato, T. Leurgans,
R. Moorhouse, J. Straube, R. Wurm, S. Heiden, A. Ergul, M. Yanagisawa, M. Barton
Life Sci 118, 77-86, 2014

Endothelin and endothelin antagonists in chronic kidney disease
D.E. Kohan, M. Barton
Kidney Int 86, 896-904, 2014

Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
Life Sci 118, 213-218, 2014

Obesity and heterozygous endothelial overexpression of prepro-endothelin-1 modulate responsiveness of mouse main and segmental renal arteries to vasoconstrictor agents
O. Baretalla, S.K. Chung, M. Barton, A. Xu, P.M. Vanhoutte
Life Sci 118, 206-212, 2014

Functional heterogenity of NADPH oxidase-mediated contractions to endothelin with vascular aging
M.R. Meyer, M. Barton, E.R Prossnitz
Life Sci 118, 226-231, 2014

Endothelin in coronary artery disease and myocardial infarction
T.M. Kolettis, M. Barton, D. Langleben, Y. Matsumura
Cardiol Rev 24, 124-220, 2013

Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013

Themed section: Endothelin
A.P. Davenport, M. Barton
Br J Pharmacol 168, 269-272, 2013

The future of endothelin research: scientific mentoring and beyond 
M. Barton, D.M. Pollock
Life Sci 91, 470-474, 2012

GPER regulates endothelin-dependent vascular tone and intracellular calcium
M.R. Meyer, A.S. Field, N.L. Kanagy, M. Barton, E.R. Prossnitz
Life Sci 91, 623-627, 2012

Endothelin in coronary artery disease and myocardial infarction
T.M. Kolettis, M. Barton, D. Langleben, Y. Matsumura
Cardiol Rev 24, 124-220, 2013

Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?
D.E. Kohan, J.G. Cleland, L.J. Rubin, D. Theodorescu, M. Barton
Life Sci 91, 528-539, 2012 

Endothelin receptor antagonists in cardiovascular medicine: Challenges and opportunities
M. Barton
In: Translational Vascular Medicine (D. Abraham, Ed) Springer London, 231-259, 2012

Endothelin and the podocyte
M. Barton, P.L. Tharaux
Clin Kidney J 5, 17-27, 2012

Endothelin XII - Editorial
M. Barton, M. Yanagisawa, P.M. Vanhoutte, T. Masaki
Life Sci 91, 449-451, 2012 

The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011
M. Barton, A.P. Davenport
Life Sci 91, 462-465, 2012

The First Tomoh Masaki Award (2011)
M. Barton, N. Emoto, T. Miyauchi
Life Sci 91, 466-469, 2012 

Endothelin antagonists in clinical trials: Lessons learned
M. Barton, D.E. Kohan
Contrib Nephrol 172, 255-260, 2011

Endothelin and podocyte injury in chronic kidney disease
C. Fligny, M. Barton, P.L. Tharaux
Contrib Nephrol 172, 120-138, 2011

Endothelin antagonism and reversal of proteinuric renal disease in humans
M. Barton
Contrib Nephrol 172, 210-222, 2011

Endothelin in renal physiology and disease
Contrib Nephrol 172 (M. Barton, D.E. Kohan, Eds), Karger, Basel, 1-266, 2011

Anti-inflammatory effects of endothelin receptor antagonists and their importance for treating human disease
M. Barton, P.C. Nett, K. Amann, M.M. Teixeira
Front Cardiovasc Drug Discov 1, 236-258, 2010

Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans
M. Barton
Biochim Biophys Acta 1802, 1203-1213, 2010

Reversal of proteinuric renal disease and the emerging role of endothelin
M. Barton
Nature Clin Pract Nephrol 4, 490-498, 2008

Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes
J. Ortmann, P.C. Nett, J. Celeiro, R. Hofmann-Lehmann, L. Tornillo, L.M. Terraciano, M. Barton
Exp Biol Med (Maywood) 231, 1030-1033, 2006

Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats
T. Traupe, J. Ortmann, E. Haas, K. Münter, N. Parekh, R. Hofmann-Lehmann, K. Baumann, M. Barton
J Cardiovasc Pharmacol 47, 456-462, 2006

Anatomically distinct activation of endothelin-3 and the L-arginine/nitric oxide pathway in the kidney with advanced aging
T. Lattmann, S. Shaw, K. Münter, W. Vetter, M. Barton
Biochem Biophys Res Commun 327, 234-241, 2005

Ageing as a determinant of renal and vascular disease: role of endothelial factors
M. Barton
Nephrol Dial Transplant 20, 485-490, 2005

Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition
J. Ortmann, K. Amann, R.P. Brandes, M. Kretzler, K. Münter, N. Parekh, T. Traupe, M. Lange, T. Lattmann, M. Barton
Hypertension 44, 974-981, 2004

Inverse regulation of endothelin-1 and nitric oxide metabolites in tissue with aging: implications
for the age-dependent increase of cardiorenal disease
M. Barton, T. Lattmann, L.V. d'Uscio, T.F. Lüscher, S. Shaw
J Cardiovasc Pharmacol 36 (Suppl.1), S153-S156, 2000

Endothelin regulates angiotensin-converting enzyme in the mouse kidney
M. Barton, R. Carmona, J.E. Krieger, W. Göettsch, H. Morawietz, L.V. d'Uscio, T. Lattmann, T.F. Lüscher, S. Shaw
J Cardiovasc Pharmacol 36 (Suppl.1), S244-S247, 2000

Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo.
Evidence for a regulatory role of endothelin
M. Barton, R. Carmona, H. Morawietz, L.V. d'Uscio, W. Goettsch, H. Hillen, C.C. Haudenschild, J.E. Krieger,
K. Münter, T. Lattmann, T.F. Lüscher, S. Shaw
Hypertension 35, 329-336, 2000

Weitere Informationen

Keywords / Suchbegriffe endothelin, renal failure, endothelin receptor, drug treatment, proteinuria, podocyte
Project leadership and contacts /
Projektleitung und Kontakte
Prof. Matthias Barton (Project Leader)
Dr. Matthias Meyer  
Other links to external web pages
Funding source(s) /
Unterstützt durch
SNF (Personen- und Projektförderung), Others
In collaboration with /
In Zusammenarbeit mit
Prof. Donald E. Kohan, University of Utah, Salt Lake City
Prof. David M. Pollock, Georgia Health Sciences University, Augusta
United States
Prof. Kerstin Amann, University of Erlangen-Nuremberg Germany
Duration of Project / Projektdauer Jan 2005 to Dec 2020